Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Historical Valuation Ratios (Summary)

Thermo Fisher Scientific Inc., historical price multiples (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).


The valuation ratios exhibit varied trends over the observed period. Generally, the ratios demonstrate fluctuations, with some indication of peaking in the first half of 2023 before experiencing declines and subsequent stabilization or renewed increases towards the end of the period. A notable pattern emerges where ratios tend to increase from the April to July reporting periods, followed by a decrease in the October reporting period, and then a subsequent increase towards the end of the year.

Price to Earnings (P/E)
The Price to Earnings ratio increased from 28.15 in April 2022 to a high of 37.81 in June 2024. A subsequent decrease was observed, falling to 24.55 in March 2025, before recovering to 28.82 by December 2025. This suggests periods of increased investor optimism followed by corrections, potentially linked to earnings performance or broader market conditions. The ratio shows a general increase from the beginning of the period to mid-2024, followed by a decline and partial recovery.
Price to Operating Profit (P/OP)
Similar to the P/E ratio, the Price to Operating Profit ratio also peaked in the first half of 2023, reaching 31.55 in July 2023. It then decreased to 27.65 by December 2024, and increased to 24.94 by December 2025. The trend mirrors that of the P/E ratio, indicating a consistent relationship between earnings and operating profit multiples. The ratio experienced a general upward trend until mid-2023, followed by a decline and stabilization.
Price to Sales (P/S)
The Price to Sales ratio demonstrated a more moderate fluctuation. It began at 5.20 in April 2022, peaked at 5.55 in June 2024, and then decreased to 4.34 by December 2025. This ratio appears less volatile than the earnings-based multiples, suggesting a more stable valuation relative to revenue. The ratio shows a slight upward trend overall, with fluctuations around the 4.8 to 5.5 range.
Price to Book Value (P/BV)
The Price to Book Value ratio followed a similar pattern to the other ratios, increasing from 5.23 in April 2022 to 4.99 in April 2023, then declining to 3.24 in March 2025, and recovering to 3.62 by December 2025. This suggests that the market’s valuation of the company’s net assets has fluctuated over the period. The ratio experienced a notable decline in the latter part of the observed timeframe.

Overall, the observed ratios suggest a period of dynamic valuation. The initial increases in multiples may reflect positive market sentiment or growth expectations. The subsequent declines could be attributed to factors such as profit-taking, changing market conditions, or concerns about future performance. The stabilization or slight recovery in the later periods indicates a potential re-evaluation of the company’s prospects.


Price to Earnings (P/E)

Thermo Fisher Scientific Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Net income attributable to Thermo Fisher Scientific Inc. (in millions)
Earnings per share (EPS)2
Share price1, 3
Valuation Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
EPS = (Net income attributable to Thermo Fisher Scientific Inc.Q4 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

5 Click competitor name to see calculations.


The price-to-earnings (P/E) ratio exhibited fluctuations over the observed period, spanning from April 2022 to December 2025. An initial period of relative stability was followed by a period of increased volatility, with subsequent stabilization towards the end of the observation window.

Initial Trend (Apr 2, 2022 – Dec 31, 2022)
The P/E ratio began at 28.15 and generally increased, reaching a peak of 31.09 in July 2022 before declining to 27.64 in October 2022. It then recovered to 30.55 by the end of 2022, indicating moderate investor optimism during this timeframe. This period coincided with a relatively stable earnings per share (EPS).
Increased Volatility (Apr 1, 2023 – Sep 30, 2023)
The first half of 2023 saw a significant increase in the P/E ratio, peaking at 37.01 in July 2023. This coincided with a decrease in EPS. A subsequent and substantial decline in the P/E ratio to 29.57 was observed by September 2023, suggesting a correction in market valuation relative to earnings. This period demonstrates increased investor sensitivity to earnings changes.
Stabilization and Decline (Dec 31, 2023 – Mar 29, 2025)
From December 2023 through March 2025, the P/E ratio demonstrated a more moderate range, fluctuating between 32.03 and 37.81. A notable decrease was then observed, falling to 24.55 by March 2025. This decline occurred alongside increasing EPS, suggesting a potential undervaluation or a shift in investor expectations. The ratio then experienced a slight recovery to 26.56 in June 2025.
Recent Period (Jun 28, 2025 – Dec 31, 2025)
The P/E ratio increased to 32.45 in September 2025, before decreasing to 28.82 by December 2025. This final period suggests a return towards a more moderate valuation, with the ratio remaining within the range observed earlier in the period. EPS continued to increase during this time.

Overall, the P/E ratio demonstrated a dynamic relationship with earnings per share. Periods of increasing P/E ratios were not always aligned with increasing EPS, indicating shifts in investor sentiment and market expectations. The latter portion of the observed period suggests a potential stabilization, although continued monitoring is warranted to confirm this trend.


Price to Operating Profit (P/OP)

Thermo Fisher Scientific Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Operating income (in millions)
Operating profit per share2
Share price1, 3
Valuation Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Operating profit per share = (Operating incomeQ4 2025 + Operating incomeQ3 2025 + Operating incomeQ2 2025 + Operating incomeQ1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

5 Click competitor name to see calculations.


The Price to Operating Profit (P/OP) ratio exhibited considerable fluctuation over the observed period, spanning from April 2022 to December 2025. Initial values indicated a relatively stable range, followed by periods of both increase and decrease. A general observation suggests a potential stabilization towards the end of the period, though volatility remains a characteristic of this ratio.

Initial Period (Apr 2, 2022 – Dec 31, 2022)
The P/OP ratio began at 21.84 and increased to a peak of 25.30 by December 2022. This initial period demonstrates an upward trend, suggesting increasing investor confidence relative to operating profitability. However, the ratio experienced intermediate fluctuations, indicating some degree of market sensitivity.
Expansion and Peak (Apr 1, 2023 – Jul 1, 2023)
The ratio continued its upward trajectory, reaching a high of 31.55 in July 2023. This represents the highest value observed throughout the entire period. The concurrent decrease in operating profit per share during this timeframe suggests the price increase outpaced earnings growth.
Subsequent Decline and Volatility (Sep 30, 2023 – Mar 29, 2025)
Following the peak, the P/OP ratio experienced a significant decline to 21.64 by March 2025. This period was characterized by substantial volatility, with fluctuations occurring in each subsequent quarter. The decline likely reflects a correction in valuation, potentially driven by changing market conditions or investor reassessment of future earnings potential. A subsequent increase to 23.62 was observed.
Final Period (Jun 28, 2025 – Dec 31, 2025)
The ratio demonstrated further fluctuation, reaching 28.40 in September 2025 before decreasing to 24.94 by December 2025. This final period suggests continued market uncertainty and a lack of a clear directional trend. The operating profit per share increased during this period, potentially mitigating further declines in the P/OP ratio.
Correlation with Operating Profit per Share
An inverse relationship between the P/OP ratio and operating profit per share is observable. Periods of decreasing operating profit per share often coincided with increases in the P/OP ratio, and vice versa. This suggests that investor sentiment and market expectations play a significant role in determining the ratio, alongside underlying profitability.

In summary, the P/OP ratio demonstrated a dynamic pattern over the analyzed timeframe. While initial periods showed an upward trend, subsequent periods were marked by volatility and a general decline, followed by some stabilization. The ratio’s movements appear to be influenced by both changes in share price and fluctuations in operating profit per share, indicating a complex interplay of market forces and company performance.


Price to Sales (P/S)

Thermo Fisher Scientific Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Revenues (in millions)
Sales per share2
Share price1, 3
Valuation Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Sales per share = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

5 Click competitor name to see calculations.


The price-to-sales (P/S) ratio exhibited fluctuations over the observed period, spanning from April 2022 to December 2025. Initially, the ratio demonstrated an increasing trend, followed by a period of decline and subsequent stabilization with renewed increases towards the end of the period.

Initial Trend (Apr 2, 2022 – Jul 2, 2022)
The P/S ratio increased from 5.20 to 5.40, indicating a growing investor willingness to pay for each dollar of sales. This initial increase suggests positive market sentiment during this timeframe.
Decline (Jul 2, 2022 – Sep 30, 2023)
A notable decline in the P/S ratio was observed, decreasing from 5.40 to 4.05. This decrease could be attributed to various factors, including broader market corrections, company-specific concerns, or a reassessment of growth prospects. The lowest point within this period was 4.05.
Stabilization and Rebound (Dec 31, 2023 – Jun 28, 2025)
Following the decline, the P/S ratio showed a period of stabilization and then a rebound. It increased from 4.99 in December 2023 to 5.55 in June 2025. This suggests a renewed investor confidence and potentially improved company performance or outlook. However, a slight decrease to 5.20 was observed in December 2025.
Volatility
The P/S ratio demonstrated considerable volatility throughout the period. The highest recorded value was 5.55 (June 2024), while the lowest was 3.73 (March 2025). This volatility suggests sensitivity to market conditions and investor perceptions.
Relationship to Share Price and Sales per Share
The P/S ratio’s movements correlate with changes in both share price and sales per share. Increases in the ratio generally coincide with increases in share price, while decreases in sales per share can contribute to a lower P/S ratio. The interplay between these two components drives the overall trend in the P/S ratio.

In conclusion, the P/S ratio experienced a dynamic period, characterized by initial growth, a subsequent decline, and a later recovery. The observed fluctuations highlight the importance of considering broader market conditions and company-specific factors when interpreting this valuation metric.


Price to Book Value (P/BV)

Thermo Fisher Scientific Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Total Thermo Fisher Scientific Inc. shareholders’ equity (in millions)
Book value per share (BVPS)2
Share price1, 3
Valuation Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
BVPS = Total Thermo Fisher Scientific Inc. shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

5 Click competitor name to see calculations.


The price-to-book value (P/BV) ratio exhibited fluctuations over the analyzed period, spanning from April 2022 to December 2025. Initially, the ratio demonstrated an increasing trend, followed by periods of decline and subsequent stabilization. A general observation suggests a moderate correlation between share price movements and book value per share, though the P/BV ratio’s behavior indicates more complex market dynamics at play.

Initial Trend (Apr 2, 2022 – Jul 2, 2022)
The P/BV ratio increased from 5.23 to 5.47. This coincided with an increase in both share price and book value per share, suggesting positive investor sentiment and underlying asset growth.
Decline and Stabilization (Jul 2, 2022 – Oct 1, 2022)
A notable decrease in the P/BV ratio occurred, falling to 4.46 by October 1, 2022. This decline was primarily driven by a more significant decrease in share price than in book value per share, potentially indicating emerging market concerns or company-specific headwinds. The ratio partially recovered to 4.83 by the end of 2022.
Fluctuations and Peak (Apr 1, 2023 – Jun 29, 2024)
The P/BV ratio experienced continued volatility, ranging from approximately 4.84 to 4.99. A slight peak was observed in June 2024 at 4.96, accompanied by a corresponding increase in share price and book value per share. This suggests a period of relative stability and investor confidence.
Significant Decline and Recovery (Jun 29, 2024 – Sep 27, 2025)
A substantial decline in the P/BV ratio was observed from 4.96 to a low of 3.24 in March 2025. This was largely attributable to a significant drop in share price, while book value per share remained relatively stable. The ratio then began a recovery, reaching 4.18 by September 2025, indicating a potential shift in market perception. The ratio concluded the period at 3.62 in December 2025.
Book Value Per Share Trend
Book value per share consistently increased throughout the period, rising from 104.62 to 143.77. This demonstrates consistent growth in net assets attributable to common shareholders. However, the P/BV ratio’s fluctuations suggest that market valuation did not always directly correlate with this underlying asset growth.

In summary, the P/BV ratio demonstrated a dynamic pattern over the analyzed timeframe. While book value per share exhibited consistent growth, the P/BV ratio was subject to market sentiment, share price volatility, and potentially other external factors. The observed declines in the ratio, particularly in late 2022 and early 2025, warrant further investigation to understand the underlying causes and their potential implications.